Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1992 Feb;60(2):536–541. doi: 10.1128/iai.60.2.536-541.1992

Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

C O Tacket 1, D M Hone 1, R Curtiss 3rd 1, S M Kelly 1, G Losonsky 1, L Guers 1, A M Harris 1, R Edelman 1, M M Levine 1
PMCID: PMC257661  PMID: 1730487

Abstract

Three attenuated Salmonella typhi strains have been constructed by introducing deletions in aroC and aroD or deletions in cya and crp into one of two wild-type parent strains, Ty2 or ISP1820. These mutant strains were designated CVD 906 (ISP1820 delta aroC delta aroD), CVD 908 (Ty2 delta aroC delta aroD), and chi 3927 (Ty2 delta cya delta crp). Two studies were conducted with 36 healthy adult inpatient volunteers to determine in a double-blind fashion the safety and immunogenicity of approximately 5 x 10(4) and 5 x 10(5) CFU of each of these three vaccine candidates given as a single dose. No statistically significant difference in the incidence of reactions among vaccinees was observed. Fever (oral temperature greater than or equal to 38.2 degrees C) occurred in 2 of 12 volunteers who received CVD 906, in 0 of 12 who received CVD 908, and in 1 of 12 who received chi 3927. Vaccine bacteremia without symptoms occurred in 1 of 12 vaccinees who received CVD 906, in 0 of 12 who received CVD 908, and in 2 of 12 who received chi 3927. Overall, 19 (53%) of 36 vaccinees developed immunoglobulin G antibody to S. typhi lipopolysaccharide after vaccination, with no statistically significant differences in the rate of seroconversion among volunteers in the three groups. We conclude that defined mutations in the aromatic biosynthetic pathway and in the cyclic AMP global regulatory system attenuate S. typhi. Mutant strains CVD 906, CVD 908, and chi 3927 are highly (and approximately equally) immunogenic but possibly differ in their propensity to induce fever. Further studies are needed to document the apparent relative safety of CVD 908 as a typhoid vaccine and as a vaccine carrier of foreign antigens.

Full text

PDF
536

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black R. E., Levine M. M., Clements M. L., Losonsky G., Herrington D., Berman S., Formal S. B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J Infect Dis. 1987 Jun;155(6):1260–1265. doi: 10.1093/infdis/155.6.1260. [DOI] [PubMed] [Google Scholar]
  2. Black R., Levine M. M., Young C., Rooney J., Levine S., Clements M. L., O'Donnell S., Hugues T., Germanier R. Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules. Dev Biol Stand. 1983;53:9–14. [PubMed] [Google Scholar]
  3. Curtiss R., 3rd, Kelly S. M. Salmonella typhimurium deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. Infect Immun. 1987 Dec;55(12):3035–3043. doi: 10.1128/iai.55.12.3035-3043.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dougan G., Chatfield S., Pickard D., Bester J., O'Callaghan D., Maskell D. Construction and characterization of vaccine strains of Salmonella harboring mutations in two different aro genes. J Infect Dis. 1988 Dec;158(6):1329–1335. doi: 10.1093/infdis/158.6.1329. [DOI] [PubMed] [Google Scholar]
  5. Forrest B. D. Identification of an intestinal immune response using peripheral blood lymphocytes. Lancet. 1988 Jan 16;1(8577):81–83. doi: 10.1016/s0140-6736(88)90284-x. [DOI] [PubMed] [Google Scholar]
  6. Gaines S., Sprinz H., Tully J. G., Tigertt W. D. Studies on infection and immunity in experimental typhoid fever. VII. The distribution of Salmonella typhi in chimpanzee tissue following oral challenge, and the relationship between the numbers of bacilli and morphologic lesions. J Infect Dis. 1968 Jun;118(3):293–306. doi: 10.1093/infdis/118.3.293. [DOI] [PubMed] [Google Scholar]
  7. Germanier R., Füer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J Infect Dis. 1975 May;131(5):553–558. doi: 10.1093/infdis/131.5.553. [DOI] [PubMed] [Google Scholar]
  8. Hoiseth S. K., Stocker B. A. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 1981 May 21;291(5812):238–239. doi: 10.1038/291238a0. [DOI] [PubMed] [Google Scholar]
  9. Hone D. M., Attridge S. R., Forrest B., Morona R., Daniels D., LaBrooy J. T., Bartholomeusz R. C., Shearman D. J., Hackett J. A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans. Infect Immun. 1988 May;56(5):1326–1333. doi: 10.1128/iai.56.5.1326-1333.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hornick R. B., Greisman S. E., Woodward T. E., DuPont H. L., Dawkins A. T., Snyder M. J. Typhoid fever: pathogenesis and immunologic control. N Engl J Med. 1970 Sep 24;283(13):686–691. doi: 10.1056/NEJM197009242831306. [DOI] [PubMed] [Google Scholar]
  11. Johnson P. C. Typhoid tonsillitis. JAMA. 1980 Jul 25;244(4):362–362. [PubMed] [Google Scholar]
  12. Jones P. W., Dougan G., Hayward C., Mackensie N., Collins P., Chatfield S. N. Oral vaccination of calves against experimental salmonellosis using a double aro mutant of Salmonella typhimurium. Vaccine. 1991 Jan;9(1):29–34. doi: 10.1016/0264-410x(91)90313-u. [DOI] [PubMed] [Google Scholar]
  13. Killar L. M., Eisenstein T. K. Immunity to Salmonella typhimurium infection in C3H/HeJ and C3H/HeNCrlBR mice: studies with an aromatic-dependent live S. typhimurium strain as a vaccine. Infect Immun. 1985 Mar;47(3):605–612. doi: 10.1128/iai.47.3.605-612.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Levine M. M., Bergquist E. J., Nalin D. R., Waterman D. H., Hornick R. B., Young C. R., Sotman S. Escherichia coli strains that cause diarrhoea but do not produce heat-labile or heat-stable enterotoxins and are non-invasive. Lancet. 1978 May 27;1(8074):1119–1122. doi: 10.1016/s0140-6736(78)90299-4. [DOI] [PubMed] [Google Scholar]
  15. Levine M. M., Ferreccio C., Black R. E., Tacket C. O., Germanier R. Progress in vaccines against typhoid fever. Rev Infect Dis. 1989 May-Jun;11 (Suppl 3):S552–S567. doi: 10.1093/clinids/11.supplement_3.s552. [DOI] [PubMed] [Google Scholar]
  16. Levine M. M., Herrington D., Murphy J. R., Morris J. G., Losonsky G., Tall B., Lindberg A. A., Svenson S., Baqar S., Edwards M. F. Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans. J Clin Invest. 1987 Mar;79(3):888–902. doi: 10.1172/JCI112899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Levine M. M., Hone D., Tacket C., Ferreccio C., Cryz S. Clinical and field trials with attenuated Salmonella typhi as live oral vaccines and as "carrier" vaccines. Res Microbiol. 1990 Sep-Oct;141(7-8):807–816. doi: 10.1016/0923-2508(90)90114-6. [DOI] [PubMed] [Google Scholar]
  18. Losonsky G. A., Ferreccio C., Kotloff K. L., Kaintuck S., Robbins J. B., Levine M. M. Development and evaluation of an enzyme-linked immunosorbent assay for serum Vi antibodies for detection of chronic Salmonella typhi carriers. J Clin Microbiol. 1987 Dec;25(12):2266–2269. doi: 10.1128/jcm.25.12.2266-2269.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Robertsson J. A., Lindberg A. A., Hoiseth S., Stocker B. A. Salmonella typhimurium infection in calves: protection and survival of virulent challenge bacteria after immunization with live or inactivated vaccines. Infect Immun. 1983 Aug;41(2):742–750. doi: 10.1128/iai.41.2.742-750.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Smith B. P., Reina-Guerra M., Hoiseth S. K., Stocker B. A., Habasha F., Johnson E., Merritt F. Aromatic-dependent Salmonella typhimurium as modified live vaccines for calves. Am J Vet Res. 1984 Jan;45(1):59–66. [PubMed] [Google Scholar]
  21. Stocker B. A., Hoiseth S. K., Smith B. P. Aromatic-dependent "Salmonella sp." as live vaccine in mice and calves. Dev Biol Stand. 1983;53:47–54. [PubMed] [Google Scholar]
  22. Tacket C. O., Forrest B., Morona R., Attridge S. R., LaBrooy J., Tall B. D., Reymann M., Rowley D., Levine M. M. Safety, immunogenicity, and efficacy against cholera challenge in humans of a typhoid-cholera hybrid vaccine derived from Salmonella typhi Ty21a. Infect Immun. 1990 Jun;58(6):1620–1627. doi: 10.1128/iai.58.6.1620-1627.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tacket C. O., Losonsky G., Taylor D. N., Baron L. S., Kopecko D., Cryz S., Levine M. M. Lack of immune response to the Vi component of a Vi-positive variant of the Salmonella typhi live oral vaccine strain Ty21a in human studies. J Infect Dis. 1991 Apr;163(4):901–904. doi: 10.1093/infdis/163.4.901. [DOI] [PubMed] [Google Scholar]
  24. Van de Verg L., Herrington D. A., Murphy J. R., Wasserman S. S., Formal S. B., Levine M. M. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect Immun. 1990 Jun;58(6):2002–2004. doi: 10.1128/iai.58.6.2002-2004.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES